Loading...
•
Dec 31, 2021
Personalis Q4 2021 Earnings Report
Personalis reported a 3% increase in quarterly revenue, driven by a 102% increase in revenue from biopharma and other customers, excluding VA MVP, which was partially offset by a decrease in VA MVP revenue.
Key Takeaways
Personalis, Inc. reported financial results for the fourth quarter and full year ended December 31, 2021. The company's quarterly revenue increased by 3% compared to the fourth quarter of 2020. Revenue from biopharma and other customers, excluding the VA MVP, increased by 102%.
Reported quarterly revenue of $20.7 million, a 3% increase compared to Q4 2020.
Revenue from biopharma and other customers, excluding the VA MVP, increased by 102%.
Launched tumor-informed liquid biopsy assay, NeXT PersonalTM in December 2021.
Received first customer order for NeXT Personal in the first quarter of 2022 from a top global pharmaceutical company.
Forward Guidance
Personalis expects total company revenue to be approximately $67.0 million for the full year of 2022. Revenue from biopharma and all other customers, excluding the VA MVP, is expected to be approximately $60.0 million, an increase of 51% compared with 2021. Net loss is expected to be in the range of $110.0 million to $115.0 million.
Positive Outlook
- Total company revenue is expected to be approximately $67.0 million.
- Revenue from biopharma and all other customers, excluding the VA MVP, is expected to be approximately $60.0 million.
- Revenue from biopharma and all other customers, excluding the VA MVP, is expected to increase of 51% compared with 2021.
Challenges Ahead
- Net loss is expected to be in the range of $110.0 million to $115.0 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...